These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 17449347

  • 21. Molecular markers and genetics in cancer development.
    Hormi-Carver K, Souza RF.
    Surg Oncol Clin N Am; 2009 Jul; 18(3):453-67. PubMed ID: 19500736
    [Abstract] [Full Text] [Related]

  • 22. Advanced pathology under squamous epithelium on initial EMR specimens in patients with Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma: implications for surveillance and endotherapy management.
    Chennat J, Ross AS, Konda VJ, Lin S, Noffsinger A, Hart J, Waxman I.
    Gastrointest Endosc; 2009 Sep; 70(3):417-21. PubMed ID: 19555948
    [Abstract] [Full Text] [Related]

  • 23. The use of dynamic positron emission tomography imaging for evaluating the carcinogenic progression of intestinal metaplasia to esophageal adenocarcinoma.
    Li Y, Woodall C, Wo JM, Zheng H, Ng CK, Ray MB, Martin RC.
    Cancer Invest; 2008 Sep; 26(3):278-85. PubMed ID: 18317969
    [Abstract] [Full Text] [Related]

  • 24. Total endoscopic eradication of Barrett's esophagus: study methodology, candidate selection, and clinical outcomes.
    Shaheen NJ, Spechler SJ.
    Endoscopy; 2008 Dec; 40(12):994-9. PubMed ID: 19065482
    [No Abstract] [Full Text] [Related]

  • 25. Where are you and how do we find you? The dilemma of identifying Barrett's epithelium before adenocarcinoma of the esophagus.
    Wong RK, Altekruse SF.
    Am J Gastroenterol; 2009 Jun; 104(6):1363-5. PubMed ID: 19436281
    [Abstract] [Full Text] [Related]

  • 26. What's new in columnar lined esophagus (Barrett's metaplasia)?
    Tadiparthi R, Bansal A, Sharma P.
    Curr Opin Gastroenterol; 2008 Jul; 24(4):516-20. PubMed ID: 18622169
    [Abstract] [Full Text] [Related]

  • 27. Histology of metaplasia and dysplasia in Barrett's esophagus.
    Yerian L.
    Surg Oncol Clin N Am; 2009 Jul; 18(3):411-22. PubMed ID: 19500733
    [Abstract] [Full Text] [Related]

  • 28. Epidemiology and molecular biology of Barrett esophagus.
    Casson AG, Williams L, Guernsey DL.
    Semin Thorac Cardiovasc Surg; 2005 Jul; 17(4):284-91. PubMed ID: 16428034
    [Abstract] [Full Text] [Related]

  • 29. Poor interobserver agreement in the distinction of high-grade dysplasia and adenocarcinoma in pretreatment Barrett's esophagus biopsies.
    Downs-Kelly E, Mendelin JE, Bennett AE, Castilla E, Henricks WH, Schoenfield L, Skacel M, Yerian L, Rice TW, Rybicki LA, Bronner MP, Goldblum JR.
    Am J Gastroenterol; 2008 Sep; 103(9):2333-40; quiz 2341. PubMed ID: 18671819
    [Abstract] [Full Text] [Related]

  • 30. Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa--significance of sampling.
    Werther M, Saure C, Pahl R, Schorr F, Rüschoff J, Alles JU, Heinmöller E.
    Pathol Res Pract; 2008 Sep; 204(5):285-94. PubMed ID: 18337019
    [Abstract] [Full Text] [Related]

  • 31. Gastroesophageal reflux disease and Barrett's esophagus.
    Anand O, Wani S, Sharma P.
    Endoscopy; 2008 Feb; 40(2):126-30. PubMed ID: 18058620
    [No Abstract] [Full Text] [Related]

  • 32. Barrett's oesophagus--a pathologist's view.
    Fléjou JF, Svrcek M.
    Histopathology; 2007 Jan; 50(1):3-14. PubMed ID: 17204017
    [Abstract] [Full Text] [Related]

  • 33. Cellular and molecular mechanisms responsible for progression of Barrett's metaplasia to esophageal carcinoma.
    Beilstein M, Silberg D.
    Gastroenterol Clin North Am; 2002 Jun; 31(2):461-79, ix. PubMed ID: 12134613
    [Abstract] [Full Text] [Related]

  • 34. Methylation of APC, TIMP3, and TERT: a new predictive marker to distinguish Barrett's oesophagus patients at risk for malignant transformation.
    Clément G, Braunschweig R, Pasquier N, Bosman FT, Benhattar J.
    J Pathol; 2006 Jan; 208(1):100-7. PubMed ID: 16278815
    [Abstract] [Full Text] [Related]

  • 35. Barrett's esophagus: can biomarkers predict progression to malignancy?
    Tischoff I, Tannapfel A.
    Expert Rev Gastroenterol Hepatol; 2008 Oct; 2(5):653-63. PubMed ID: 19072343
    [Abstract] [Full Text] [Related]

  • 36. p53 and the malignant progression of Barrett's esophagus.
    Merola E, Claudio PP, Giordano A.
    J Cell Physiol; 2006 Mar; 206(3):574-7. PubMed ID: 16110481
    [Abstract] [Full Text] [Related]

  • 37. Intestinal metaplasia is the probable common precursor of adenocarcinoma in Barrett's esophagus and adenocarcinoma of the gastrica cardia.
    Conio M, Cameron AJ.
    Gastrointest Endosc; 2001 Dec; 54(6):799-801. PubMed ID: 11762326
    [No Abstract] [Full Text] [Related]

  • 38. Understanding cancer incidence in Barrett's esophagus: light at the end of the tunnel.
    Corley DA.
    J Natl Cancer Inst; 2011 Jul 06; 103(13):994-5. PubMed ID: 21680911
    [No Abstract] [Full Text] [Related]

  • 39. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
    Hillman LC, Chiragakis L, Shadbolt B, Kaye GL, Clarke AC.
    Aliment Pharmacol Ther; 2008 Feb 15; 27(4):321-6. PubMed ID: 18047565
    [Abstract] [Full Text] [Related]

  • 40. Treatment of Barrett's esophagus with high-grade dysplasia.
    McAllaster JD, Buckles D, Al-Kasspooles M.
    Expert Rev Anticancer Ther; 2009 Mar 15; 9(3):303-16. PubMed ID: 19275509
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.